Duke Immune Profiling Core (DIPC)

Overview

The Duke Immune Profiling Core (DIPC) is a Duke School of Medicine and Duke Cancer Center Institute Service Center whose academic home resides in the Department of Surgery. Our overarching mission, "To identify immunologic signatures that predict clinical outcomes," comprises two components. The first is a Service component in which DIPC provides comprehensive, highly standardized, state-of-the-art human immunologic profiling services in support of both intra- and extramural translational research endeavors, including Phase I/II clinical trials. The second DIPC component focuses on Discovery, and utilizes advanced, high-dimensional Core technologies and resources to stimulate novel translational research initiatives that will impact the existing "standard of medical care." With over 35 years of experience in flow cytometry and immune profiling, we are available to support a wide range of services, such as small-scale projects for generating pilot data extending through clinical trial testing. Additionally, our services extend to single-cell proteomics and multiplex immunoassays, study planning, performing experiments, data collection and analysis, and writing support.

• Biosample Processing and Biorepository

• Immune Phenotyping by Polychromatic Flow Cytometry

• Multiplex Immunoassays

• Chip-Based Single Cell Proteomics Assays (Isolight)

• Bioinformatics and Biostatistics

• Computer Stations for Data Analysis

Please contact us at duke.ipc@dm.duke.edu for a current pricing list. 

DIPC Leadership

• Kent J. Weinhold, PhD (Director)
• Smita Nair, PhD
• Lynn Lin, PhD (Bioinformatics & Biostatistics)

DIPC Staff

• Jennifer Enzor
• Victoria Little
• Preksha Patel

Immune profiling for vaccine trials

• From a multimillion dollar grant from NIH, DIPC will assess the cellular immune responses of volunteers in a malaria vaccine trials through the Vaccine Trials Evaluation Unit (VTEU).
   

Immune profiling for cancer immunotherapy trials

1. Neoadjuvant ipilimumab therapy for non-small cell lung cancer (NSCLC); NCT01820754
2. Neoadjuvant Pembrolizumab therapy or non-small cell lung cancer; NCT02818920
3. Evaluation of nivolumab alone versus nivolumab + ipilimumab therapy for recurrent glioblastomas; NCT02017717
4. Treatment of urothelial cancers with pembrolizumab alone versus pembrolizumab + ACP196 (a BTK inhibitor); IND#124755
5. Evaluation of anti-tumor reactivities in the lymph node and PBMC of metastatic, castrate-resistant prostate cancer patientsbefore or after receiving treatment with sipuleucel-T; NCT02036918NCT02036918
6. A randomized trial of Pembrolizumab and radiotherapy verus radiotherapy in high-risk soft tissue sarcoma of the extremity; NCT03092323

Core Staff Contact

duke.ipc@dm.duke.edu
Jennifer Enzor: 919-684-3315

Surgical Oncology Research Facility (SORF)
915 South LaSalle Street Ext.
Room 120 / 122 / 124
Durham, NC 27710